Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Sensus Healthcare (Nasdaq: SRTS), a medical device company specializing in non-invasive treatments for oncological and non-oncological conditions, has announced its upcoming second quarter 2024 financial results and business update conference call. The call is scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time.
Key points:
- Management will discuss Q2 2024 financial results
- A business update and discussion on recent and upcoming milestones will be provided
- Participants can pre-register for the call or dial in directly
- A webcast will be available on the company's Investor Relations website
- A telephone replay will be accessible until September 8th
Sensus Healthcare reported a strong first-quarter financial performance with revenues up over three-fold compared to the previous year. Revenues were $10.7 million, net income was $2.3 million, and adjusted EBITDA was $3.0 million. The company launched a recurring revenue program, the 'Fair Deal Agreement', to complement its fair market value lease program. Sensus Healthcare showcased its products at key industry events and announced significant sales and developments, including a U.S. patent for SRT-100 Vision System and international sales.
Sensus Healthcare, Inc. announces the sale of an SRT-100 system to the Veterinary Specialist Referral Center in Tel Aviv, marking the first veterinary commercial sale of the device outside the U.S. This system will provide gentler radiotherapy to treat tumors in dogs and cats. The Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel, employing over 20 specialists and 30 veterinary technicians. The SRT-100 system has previously been acquired by Colorado State University for treating companion animals and conducting studies on equine ophthalmic tumors.
Sensus Healthcare, Inc. announces the sale of the first SRT-100 Vision™ system in Asia to Far Eastern Memorial Hospital in Taiwan. The hospital plans to conduct research on new indications for the system, potentially leading to global label expansion. The company is optimistic about future sales in the region and emphasizes the importance of this sale. The SRT-100 Vision system utilizes image-guided ultrasound technology and has seen recent enhancements for improved clinical outcomes. Additionally, Sensus Healthcare will host a conference call on May 9, 2024, to discuss first-quarter financial results and provide business updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.